Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Gene signature may improve colon cancer treatment

01.03.2010
A gene signature, first identified in mouse colon cancer cells, may help identify patients at risk of colon cancer recurrence, according to a recent study by Vanderbilt-Ingram Cancer Center researchers.

The findings, published in the March issue of Gastroenterology, could help personalize treatments for colon cancer — the second leading cause of cancer-related deaths in the United States — by identifying patients most likely to benefit from chemotherapy.

In its early stages, colorectal cancer is treated with surgery only. However, between 20 percent and 25 percent of patients with Stage II disease (when the tumor has penetrated the muscular wall of the colon) will experience metastatic recurrence after surgical resection alone.

For stage III, when the cancer has spread to the lymph nodes, surgery is generally followed by chemotherapy — despite research showing that about 40 percent of stage III patients treated by surgery alone do not have a recurrence of disease in five years.

This suggests that identifying stage II patients at the greatest risk for recurrence — and targeting adjuvant chemotherapy to them — could decrease recurrences in that group. In addition, those stage III patients at lowest risk, if prospectively identified, could avoid having potentially toxic chemotherapy.

Using a mouse colon cancer cell line, R. Daniel Beauchamp, M.D., the John Clinton Foshee Distinguished Professor of Surgery and chair of the Section of Surgical Sciences, and colleagues identified 300 genes that showed distinct patterns of expression related to their ability to invade into a gel-like matrix, a test that reflects the aggressiveness of cancer cells.

Statistical analysis, led by Yu Shyr, Ph.D., the Ingram Professor of Cancer Research and professor of Biostatistics, helped refine the initial set of 300 genes into a set of 34 genes that were most closely associated with metastasis and death in a set of human colon cancer samples from Vanderbilt patients.

The researchers then examined whether this 34-gene signature could predict recurrence and death in a larger patient population.

In colon cancer tissue samples from 177 patients from the H. Lee Moffitt Cancer Center in Tampa, Fla., the signature identified in the highly invasive mouse cells — the "high recurrence" (or "poor prognosis") signature — was associated with increased risk of recurrence and death across all stages of disease.

Among patients with stage II disease, those with the "poor prognosis" signature had a five-year mortality rate of 31 percent. However, no stage II patients with a "low recurrence" (or "good prognosis") signature died within the five-year period.

In patients with stage III disease, 38 percent of those with a "poor" signature died of their disease within five years, whereas only 10.7 percent of those with a "good" prognosis signature died within that time period.

"Across all stages, if patients had a 'poor' prognosis signature, then they would be five times more likely to have a recurrence of cancer than those with a 'good' prognosis signature," said Beauchamp.

But the most interesting finding, Beauchamp says, is the ability of this gene signature to identify the patients most likely to benefit from chemotherapy.

Among stage III patients with a "poor" prognosis signature, those who had received chemotherapy had a 36 percent cancer-related death rate. Those who did not receive chemotherapy had an 86 percent death rate.

"That tells us that patients with the ('poor' prognosis signature) probably benefited from chemotherapy," Beauchamp said. "And (patients with a 'good' prognosis signature) appeared to get no benefit from chemotherapy."

"This really feeds right into personalized cancer medicine…in identifying subgroups of patients that will benefit from one treatment versus another treatment modality, trying to target those patients that are most likely to benefit…and not exposing patients who are less likely to benefit with potentially toxic treatments," Beauchamp said.

"Ultimately this should lead to more individualized therapy for cancer patients."

The research was supported by grants from National Institutes of Health.

Melissa Marino | EurekAlert!
Further information:
http://www.vanderbilt.edu

More articles from Life Sciences:

nachricht Bare bones: Making bones transparent
27.04.2017 | California Institute of Technology

nachricht Link Discovered between Immune System, Brain Structure and Memory
26.04.2017 | Universität Basel

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

Bare bones: Making bones transparent

27.04.2017 | Life Sciences

Study offers new theoretical approach to describing non-equilibrium phase transitions

27.04.2017 | Physics and Astronomy

From volcano's slope, NASA instrument looks sky high and to the future

27.04.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>